Multiplexing Homocysteine into First-Tier Newborn Screening Mass Spectrometry Assays Using Selective Thiol Derivatization
Clinical Chemistry · 2023
DOI: 10.1093/clinchem/hvad007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Chemistry, 2023. Verfasst von C Austin Pickens und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, United States. Hauptthemen laut MEDLINE: Neonatal Screening, Homocystinuria. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Background
Classical homocystinuria (HCU) results from deficient cystathionine β-synthase activity, causing elevated levels of Met and homocysteine (Hcy). Newborn screening (NBS) aims to identify HCU in pre-symptomatic newborns by assessing Met concentrations in first-tier screening. However, unlike Hcy, Met testing leads to a high number of false-positive and -negative results. Therefore, screening for Hcy directly in first-tier screening would be a better biomarker for use in NBS.
Methods
Dried blood spot (DBS) quality control and residual clinical specimens were used in analyses. Several reducing and maleimide reagents were investigated to aid in quantification of total Hcy (tHcy). The assay which was developed and validated was performed by flow injection analysis–tandem mass spectrometry (FIA-MS/MS).
Results
Interferents of tHcy measurement were identified, so selective derivatization of Hcy was employed. Using N-ethylmaleimide (NEM) to selectively derivatize Hcy allowed interferent-free quantification of tHcy by FIA-MS/MS in first-tier NBS. The combination of tris(2-carboxyethyl)phosphine (TCEP) and NEM yielded significantly less matrix effects compared to dithiothreitol (DTT) and NEM. Analysis of clinical specimens demonstrated that the method could distinguish between HCU-positive, presumptive normal newborns, and newborns receiving total parenteral nutrition.
Conclusions
Here we present the first known validated method capable of screening tHcy in DBS during FIA-MS/S first-tier NBS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, United States.
ORCID-Profile: Konstantinos Petritis
Zitieren
APA
Pickens, C. A., Courtney, E., Isenberg, S. L., Cuthbert, C., & Petritis, K. (2023). Multiplexing Homocysteine into First-Tier Newborn Screening Mass Spectrometry Assays Using Selective Thiol Derivatization. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvad007
Vancouver
Pickens CA, Courtney E, Isenberg SL, Cuthbert C, Petritis K. Multiplexing Homocysteine into First-Tier Newborn Screening Mass Spectrometry Assays Using Selective Thiol Derivatization. Clinical Chemistry. 2023. doi:10.1093/clinchem/hvad007
BibTeX
@article{Pickens2023,
author = {Pickens, C Austin and Courtney, Elya and Isenberg, Samantha L and Cuthbert, Carla and Petritis, Konstantinos},
title = {Multiplexing Homocysteine into First-Tier Newborn Screening Mass Spectrometry Assays Using Selective Thiol Derivatization},
journal = {Clinical Chemistry},
year = {2023},
doi = {10.1093/clinchem/hvad007}
}
EUVIMED